Literature DB >> 7437263

Pharmacokinetics of intravenous and oral prednisolone.

S Al-Habet, H J Rogers.   

Abstract

1 Doses of 16, 32, 48 and 64 mg prednisolone were administered intravenously to normal volunteers who also received 100 prednisolone orally. Plasma prednisolone concentrations were estimated by quantitative thin layer chromatography. 2 The bioavailability fraction was 1.063 +/- 0.154 (s.d.) indicating complete availability of prednisolone following oral administration. 3 The mean T 1/2 over all doses were 4.11 +/- 0.97 (s.d.) h and there was no evidence of a dose-related change in its value. 4 The mean systemic clearance over all doses was 0.104 +/- 0.034 (s.d) 1 h-1 kg-1. There was no evidence of a dose-related change in clearance or in the apparent volume of distribution (overall mean 0.588 +/- 0.152 1 kg-1). 5 The area under the plasma concentration-time curve was linearly related to dose. 6 Plasma concentration-time curves normalised for dose were superimposable. 7 It was concluded that over the dose range investigated, non-linear pharmacokinetic behaviour had not been demonstrated in this group of normal volunteers.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437263      PMCID: PMC1430141          DOI: 10.1111/j.1365-2125.1980.tb01796.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique.

Authors:  P J Morrison; I D Bradbrook; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

2.  Dose-dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J C Loo; I J McGilveray; N Jordan; J Moffat; R Brien
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

3.  Relative bioavailability of prednisone and prednisolone in man.

Authors:  F L Tse; P G Welling
Journal:  J Pharm Pharmacol       Date:  1979-07       Impact factor: 3.765

4.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

5.  Concurrent administration of antacids and prednisone: effect on serum levels of prednisolone.

Authors:  A R Tanner; J A Caffin; J W Halliday; L W Powell
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

6.  Plasma protein binding of prednisolone in normal volunteers and arthritic patients.

Authors:  I T Ağabeyoğlu; R F Bergstrom; W R Gillespie; J G Wagner; D R Kay
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

7.  Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Authors:  B H Dvorchik; E S Vessell
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

8.  Dose dependent pharmacokinetics of prednisolone.

Authors:  M E Pickup; J R Lowe; P A Leatham; V M Rhind; V Wright; W W Downie
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

9.  Anorectal pruritus after intravenous hydrocortisone sodium succinate and sodium phosphate.

Authors:  E Novak; T J Gilbertson; C E Seckman; R D Stewart; A R DiSanto; S S Stubbs
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

  9 in total
  21 in total

1.  Monocyte zinc and in vitro prostaglandin E2 and interleukin-1 beta production by cultured peripheral blood monocytes in patients with Crohn's disease.

Authors:  H F Goode; B J Rathbone; J Kelleher; B E Walker
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Dose-dependent pharmacokinetics of dexamethasone.

Authors:  D Loew; O Schuster; E H Graul
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

5.  Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone.

Authors:  C Rollin; O Chosidow; B Diquet; C Dutreuil; S Herson; J Revuz; J C Delchier
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease.

Authors:  J E Lennard-Jones
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

7.  Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.

Authors:  H Bergrem; P Grøttum; H E Rugstad
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Pharmacokinetics of prednisolone in children with the nephrotic syndrome.

Authors:  M Rostin; P Barthe; G Houin; M Alvinerie; F Bouissou
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

9.  Absorption of prednisolone in patients with Crohn's disease.

Authors:  J A Shaffer; S E Williams; L A Turnberg; J B Houston; M Rowland
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

10.  Alterations in prednisolone disposition as a result of time of administration, gender and dose.

Authors:  P J Meffin; P M Brooks; B C Sallustio
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.